

Items supported by the Samaritan Fund

(a) [Non-drug Items supported by the Fund](#)

(b) [Self-financed Drugs supported by the Samaritan Fund \(SF\) and Community Care Fund \(CCF\) Medical Assistance Programme \(First Phase Programme\) \(for specified self-financed cancer drugs\)](#)

(a) Non-drug Items supported by the Fund

1. Percutaneous Transluminal Coronary Angioplasty (PTCA) and other consumables for interventional cardiology
2. Cardiac Pacemakers
3. Myoelectric Prosthesis
4. Custom-made Prosthesis
5. Appliances for prosthetic and orthotic services, physiotherapy and occupational therapy services (including prosthesis, wheelchair, mobility & transfer aids, self care aids, therapeutic furniture, and training & treatment device & equipment)
6. Home use equipment and appliances (including hearing devices & accessories, respiratory equipment, communication aids, and infusion pump for enteral/parenteral nutrition)
7. Gamma knife surgery
8. Harvesting of marrow in a foreign country for marrow transplant

The Fund will only support the model which can meet the basic medical needs of the patients.

(b) Drugs supported by the Samaritan Fund

The following specific self-financed drugs are supported by the Samaritan Fund:

Item	Drug	Specialties	Clinical indications
1a	Abatacept	Rheumatology	Rheumatoid arthritis
1b		Paediatrics	Juvenile idiopathic arthritis
2a	Abemaciclib ^{#~}	Oncology	HR positive HER2 negative locally advanced or metastatic breast cancer (MBC)
2b	Abemaciclib [#]		
3	Fulvestrant		
4	Abiraterone [#]	Oncology	Prostate cancer
5a	Acalabrutinib [#]	Haematology	Relapsed / refractory chronic lymphocytic leukaemia (CLL)
5b			Previously untreated chronic lymphocytic leukaemia (CLL) with unmutated IGHV [^]

Item	Drug	Specialties	Clinical indications
6a	Adalimumab	Dermatology / Paediatrics	Severe psoriasis
			Hidradenitis suppurativa (acne inversa)^
6b		Ophthalmology	Non-infectious intermediate, posterior and panuveitis
6c			Paediatric chronic non-infectious anterior uveitis
6d		Paediatrics	Juvenile idiopathic arthritis
6e		Rheumatology	Ankylosing spondylitis
6f			Psoriatic arthritis
6g			Rheumatoid arthritis
7	Afatinib	Oncology	Non-small cell lung cancer with activating EGFR mutation (first-line treatment)
8a	Aflibercept	Ophthalmology	Neovascular (wet) age-related macular degeneration
8b			Macular oedema secondary to Central Retinal Vein Occlusion
8c			Visual impairment caused by diabetic macular edema
9a	Alectinib [#]	Oncology	ALK+ve non-small cell lung cancer (NSCLC) (first-line treatment)
9b			ALK+ve metastatic non-small cell lung cancer (NSCLC), progressed on Crizotinib and intolerant to Ceritinib, or have CNS-progression after Crizotinib
10	Apalutamide ^{^#}	Oncology	Prostate cancer
11	Atezolizumab [~]	Oncology	EGFR-ve and ALK-ve metastatic non-small cell lung cancer (NSCLC) progressed on or following platinum-based chemotherapy
12	Axitinib [#]	Oncology	Advanced renal cell carcinoma
13a	Azacitidine	Haematology	Acute myeloid leukaemia (AML)
13b			Chronic myelomonocytic leukaemia (CMML)
13c			Myelodysplastic syndromes (MDS)

Item	Drug	Specialties	Clinical indications
14	Baricitinib	Rheumatology	Rheumatoid arthritis
15	Belimumab	Paediatrics / Rheumatology	Systemic lupus erythematosus (SLE)
16	Bendamustine	Haematology	Chronic lymphocytic leukaemia (CLL)
17	Benralizumab	Respiratory Medicine	Severe refractory eosinophilic asthma (add-on treatment)
18	Bortezomib	Haematology	Multiple myeloma (MM)
19a	Brentuximab Vedotin	Haematology	Systemic anaplastic large cell lymphoma (sALCL)
19b			CD30+ cutaneous T-cell lymphoma (CTCL)
19c			CD30+ Hodgkin lymphoma
20a	Brigatinib [#]	Oncology	ALK+ve non-small cell lung cancer (NSCLC) (first-line treatment)
20b			ALK+ve metastatic non-small cell lung cancer (NSCLC), progressed on Crizotinib and intolerant to Ceritinib, or have CNS-progression after Crizotinib
21a	Canakinumab	Paediatrics	Cryopyrin-associated periodic syndromes
21b			Familial Mediterranean fever
21c			Hyperimmunoglobulin D syndrome / mevalonate kinase deficiency
21d			Systemic juvenile idiopathic arthritis
21e			Tumour necrosis factor receptor associated periodic syndrome
22	Carfilzomib	Haematology	Multiple myeloma (MM)
23a	Ceritinib [#]	Oncology	ALK+ve non-small cell lung cancer (NSCLC) (first line treatment)
23b			ALK+ve advanced non-small cell lung cancer (NSCLC) previously treated with Crizotinib
24a	Certolizumab Pegol	Rheumatology	Ankylosing spondylitis
24b			Psoriatic arthritis
24c			Rheumatoid arthritis

Item	Drug	Specialties	Clinical indications
25	Cetuximab	Oncology	RAS wild-type colorectal cancer
26	Cladribine	Neurology	Relapsing-remitting multiple sclerosis (RRMS)
27a	Crizotinib [#]	Oncology	ALK+ve non-small cell lung cancer (NSCLC)
27b			ROS1-positive non-small cell lung cancer (NSCLC)
28	Dabrafenib [#] and Trametinib [#]	Oncology	Skin cancer
29			
30	Daratumumab [^] and Bortezomib [^]	Haematology	Systemic AL amyloidosis
18			
31a	Dasatinib	Haematology	Imatinib-resistant chronic myeloid leukaemia (CML)
31b			Imatinib-resistant philadelphia or BCR/ABL positive acute lymphoblastic leukaemia (ALL)
31c			Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase
31d			Nilotinib-resistant chronic myeloid leukaemia (CML)
32a	Dupilumab	Dermatology / Paediatrics	Atopic dermatitis
32b		Respiratory Medicine	Severe asthma with type 2 inflammation (add-on treatment)
33	Durvalumab [~]	Oncology	Unresectable and stage III non-small cell lung cancer (NSCLC) not progressed following concurrent platinum-based chemotherapy and radiation therapy
34	Specific ultra-expensive drug <i>(The patient must be a permanent resident of the Hong Kong Special Administrative Region according to the Immigration Ordinance)</i>		
	Eculizumab	Haematology	Paroxysmal nocturnal haemoglobinuria (PNH)

Item	Drug	Specialties	Clinical indications
35a	Eltrombopag	Haematology	Chronic immune thrombocytopenia (for post-splenectomised patients; or non-splenectomised patients in whom splenectomy is contraindicated)
35b			Severe aplastic anaemia (SAA) [#]
36	Enzalutamide [#]	Oncology	Prostate cancer
37a	Etanercept	Dermatology	Severe psoriasis
37b		Paediatrics	Juvenile idiopathic arthritis
37c		Rheumatology	Ankylosing spondylitis
37d			Psoriatic arthritis
37e			Rheumatoid arthritis
38	Everolimus [#]	Oncology	HR positive HER2 negative advanced breast cancer
39	Gefitinib	Oncology	Non-small cell lung cancer with activating EGFR mutation (first-line or second-line treatment)
40	Gilteritinib ^{^#}	Haematology	Relapsed or refractory acute myeloid leukaemia (AML)
41a	Golimumab	Rheumatology	Ankylosing spondylitis
41b			Psoriatic arthritis
41c			Rheumatoid arthritis
42	Growth Hormone	Endocrinology	Dwarfism
43a	Guselkumab	Dermatology	Severe psoriasis
43b		Rheumatology	Psoriatic arthritis
44a	Ibrutinib [#]	Haematology	Relapsed or refractory mantle cell lymphoma (MCL)
44b			Chronic lymphocytic leukaemia (CLL)
45a	Infliximab	Dermatology	Severe psoriasis
45b		Rheumatology	Ankylosing spondylitis
45c			Psoriatic arthritis
45d			Rheumatoid arthritis
46	Inotuzumab Ozogamicin [~]	Haematology	Relapsed or refractory CD22-positive B cell Acute lymphoblastic leukaemia (ALL)

Item	Drug	Specialties	Clinical indications
47	Interferon	Paediatrics	Chronic granulomatous disease
48	Ixekizumab	Dermatology	Severe psoriasis
49	Lenalidomide [#]	Haematology	Multiple myeloma (MM)
50	Lenvatinib ^{~#}	Oncology	Unresectable hepatocellular carcinoma (HCC)
51	Letermovir	Haematology	Prophylaxis of cytomegalovirus reactivation and disease in recipients of an allogeneic haematopoietic stem cell transplant
52	Mepolizumab	Respiratory Medicine	Severe refractory eosinophilic asthma (add-on treatment)
53	Midostaurin [#]	Haematology	Acute myeloid leukaemia (AML)
54	Natalizumab	Neurology	Relapsing-remitting multiple sclerosis (RRMS)
55a	Nilotinib	Haematology	Dasatinib-resistant chronic myeloid leukaemia (CML)
55b			Imatinib-resistant chronic myeloid leukaemia (CML)
55c			Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase
56	Nintedanib (Ofev)	Respiratory Medicine	Idiopathic pulmonary fibrosis (IPF)
57a	Nivolumab	Oncology	Unresectable or metastatic melanoma
57b			Adjuvant treatment of melanoma with involvement of lymph nodes or metastatic disease, have undergone complete resection [~]
57c			EGFR-ve and ALK-ve metastatic non-small cell lung cancer (NSCLC) progressed on or following platinum-based chemotherapy [~]
58a	Obinutuzumab	Haematology	Follicular lymphoma
58b			Chronic lymphocytic leukaemia (CLL)
59a	Omalizumab	Respiratory Medicine	Severe persistent confirmed allergic IgE mediated asthma
59b		Clinical Immunology	Chronic spontaneous urticaria

Item	Drug	Specialties	Clinical indications
60	Osimertinib [#]	Oncology	Locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC)
61	Palbociclib [#]	Oncology	HR positive HER2 negative locally advanced or metastatic breast cancer (MBC)
62	Panitumumab	Oncology	RAS wild-type colorectal cancer
63	Pazopanib	Oncology	Advanced renal cell carcinoma
64	Pembrolizumab [~]	Oncology	First-line treatment for metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression with no EGFR or ALK genomic tumor aberrations
65	Pertuzumab and Trastuzumab	Oncology	HER2 over-expressed metastatic breast cancer (MBC)
66a			HER2 positive, locally advanced, inflammatory, or early stage breast cancer
67a	Plerixafor	Haematology	Multiple myeloma (MM)
67b			Non-Hodgkin's lymphoma (NHL)
68	Pomalidomide [#]	Haematology	Multiple myeloma (MM)
69a	Ponatinib	Haematology	Acute lymphoblastic leukaemia (ALL)
69b			Chronic myeloid leukaemia (CML)
70a	Ranibizumab	Ophthalmology	Neovascular (wet) age-related macular degeneration
70b			Macular oedema secondary to Central Retinal Vein Occlusion
70c			Visual impairment caused by diabetic macular edema
71a	Ribociclib [#]	Oncology	HR positive HER2 negative locally advanced or metastatic breast cancer (MBC)
71b	Ribociclib [#] and Fulvestrant		
3			
72	Risankizumab	Dermatology	Severe psoriasis

Item	Drug	Specialties	Clinical indications
73a	Rituximab	Haematology	Maintenance therapy for relapsed follicular lymphoma (RFL)
73b			Previously-untreated and relapsed / refractory chronic lymphocytic leukaemia (CLL)
73c		Oncology	Malignant lymphoma (ML)
73d		Paediatrics	Severe, active granulomatosis with polyangiitis (GPA)/microscopic polyangiitis (MPA)
73e			CD20 positive diffuse large B-cell lymphoma, Burkitt lymphoma / Burkitt leukaemia or Burkitt-like lymphoma
73f		Rheumatology	Refractory rheumatoid arthritis (RRA)
73g			Severe, active non-life-threatening granulomatosis with polyangiitis/microscopic polyangiitis
74	Ruxolitinib [#]	Haematology	Myelofibrosis-related splenomegaly or symptoms
75	Sarilumab	Rheumatology	Rheumatoid arthritis
76a	Secukinumab	Dermatology	Severe psoriasis
76b		Rheumatology	Ankylosing spondylitis
76c			Psoriatic arthritis
77	Siltuximab [^]	Haematology	Multicentric Castleman's disease (MCD)
78	Siponimod	Neurology	Secondary progressive multiple sclerosis (SPMS)
79	Sunitinib	Oncology	Gastrointestinal tumour
80	Temozolomide	Oncology	Recurrent high grade glioma
81a	Tocilizumab	Paediatrics	Juvenile idiopathic arthritis(JIA)
81b			Systemic juvenile idiopathic arthritis (JIA)
81c		Rheumatology	Refractory giant cell arteritis
81d			Rheumatoid arthritis
82a	Tofacitinib	Rheumatology	Rheumatoid arthritis
82b			Psoriatic arthritis

Item	Drug	Specialties	Clinical indications
83	Tolvaptan (Jinarc)	Nephrology	Autosomal dominant polycystic kidney disease (ADPKD)
66b	Trastuzumab	Oncology	HER2 over-expressed metastatic breast cancer (MBC)
66c			HER2 positive early breast cancer (EBC)
84a	Trastuzumab emtansine (T-DM1)	Oncology	HER2 positive early breast cancer (EBC)
84b			HER2 positive metastatic breast cancer (MBC)
85a	Upadacitinib	Rheumatology	Ankylosing spondylitis
85b			Psoriatic arthritis
85c			Rheumatoid arthritis
85d		Dermatology^/ Paediatrics^	Atopic dermatitis^
86a	Ustekinumab	Dermatology	Severe psoriasis
86b		Rheumatology	Psoriatic arthritis
87 13d	Venetoclax^# and Azacitidine	Haematology	Newly diagnosed acute myeloid leukaemia (AML)

Remarks:

^ With effect from 16 December 2023.

~ **Abemaciclib** for treating breast cancer; **Atezolizumab**, **Brigatinib**, **Durvalumab**, **Nivolumab** and **Pembrolizumab** for treating NSCLC; **Lenvatinib** for treating hepatocellular carcinoma; **Inotuzumab Ozogamicin** for treating acute lymphoblastic leukaemia; and **Nivolumab** for treating melanoma, are repositioned from CCF Medical Assistance Programme (First Phase Programme) to SF with effect from 16 December 2023. New applications and renewal applications approved on or after the effective date will be subsidised by SF. For applications already approved before the effective date, CCF subsidy will be provided until end of treatment of the applications.

The concerned drugs are under Capping Programmes where free drugs are subsequently provided through designated community pharmacies. For details, please refer to the [\[Information Sheet\]](#).

Self-financed Drugs supported by the Samaritan Fund (SF) and Community Care Fund (CCF) Medical Assistance Programme (First Phase Programme) (for specified self-financed cancer drugs)

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
Haematology	Acute lymphoblastic leukaemia	Dasatinib, Inotuzumab Ozogamicin~ Ponatinib	✓	
	Acute myeloid leukaemia	Gilteritinib ^{^#} , Midostaurin [#] , Venetoclax ^{^#} and Azacitidine	✓	
		Gemtuzumab Ozogamicin		✓
	Chronic immune thrombocytopenia	Eltrombopag	✓	
	Chronic lymphocytic leukaemia	Acalabrutinib ^{**} , Bendamustine, Ibrutinib ^{**} , Obinutuzumab, Rituximab	✓	
	Chronic myeloid leukaemia	Dasatinib, Nilotinib, Ponatinib	✓	
	Classical Hodgkin Lymphoma (cHL)	Pembrolizumab [*]		✓
	Diffuse large B-cell lymphoma (DLBCL)	Polatuzumab Vedotin and Rituximab and Bendamustine		✓
	Follicular lymphoma	Obinutuzumab, Rituximab	✓	
	Mantle cell lymphoma	Ibrutinib ^{**}	✓	
		Acalabrutinib ^{**}		✓
	Multicentric Castleman's disease (MCD) [^]	Siltuximab [^]	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Multiple myeloma	Bortezomib*, Carfilzomib, Lenalidomide*#, Pomalidomide #	✓	
		Daratumumab* and Bortezomib*, Isatuximab^ and Pomalidomide^#, Ixazomib# and Lenalidomide*#		✓
	Multiple myeloma / Non-Hodgkin's lymphoma	Plerixafor	✓	
	Myelodysplastic syndromes / chronic myelomonocytic leukaemia / acute myeloid leukaemia	Azacitidine	✓	
	Myelofibrosis-related splenomegaly or symptoms	Ruxolitinib#	✓	
	Paroxysmal nocturnal haemoglobinuria	Eculizumab	✓	
	Prophylaxis of cytomegalovirus reactivation and disease in recipients of an allogeneic haematopoietic stem cell transplant	Letermovir	✓	
	Severe aplastic anaemia	Eltrombopag#	✓	
	Systemic AL amyloidosis^	Daratumumab*^ and Bortezomib*	✓	
	Systemic anaplastic large cell lymphoma (sALCL)	Brentuximab Vedotin	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	CD30+ Hodgkin lymphoma/ CD30+ cutaneous T-cell lymphoma	Brentuximab Vedotin	✓	
	Waldenström's macroglobulinaemia (WM)^	Ibrutinib ^{^*#}		✓
Respiratory Medicine	Idiopathic pulmonary fibrosis	Nintedanib (Ofev)	✓	
	Severe persistent confirmed allergic IgE mediated asthma	Omalizumab	✓	
	Severe refractory eosinophilic asthma	Mepolizumab, Benralizumab	✓	
	Severe asthma with Type 2 inflammation	Dupilumab	✓	
Rheumatology	Ankylosing spondylitis	Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Secukinumab, Updacinib	✓	
	Psoriatic arthritis	Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Guselkumab, Infliximab, Secukinumab, Tofacitinib, Updacinib, Ustekinumab	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Rheumatoid arthritis	Abatacept, Adalimumab, Baricitinib, Certolizumab Pegol, Etanercept, Golimumab, Infliximab, Sarilumab, Tocilizumab, Tofacitinib, Upadacitinib	✓	
	Refractory rheumatoid arthritis	Rituximab	✓	
	Refractory giant cell arteritis	Tocilizumab	✓	
	Severe, active non-life-threatening granulomatosis with polyangiitis / microscopic polyangiitis	Rituximab	✓	
	Systemic lupus erythematosus (SLE)	Belimumab	✓	
Nephrology	Autosomal dominant polycystic kidney disease	Tolvaptan (Jinarc)	✓	
Neurology	Relapsing remitting multiple sclerosis	Cladribine, Natalizumab	✓	
	Secondary progressive multiple sclerosis (SPMS)	Siponimod	✓	
Oncology	Bladder cancer	Avelumab [^] Pembrolizumab [*]		✓

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Breast cancer	Abemaciclib ^{#~} , Abemaciclib [#] and Fulvestrant, Everolimus [#] , Palbociclib [#] , Pertuzumab and Trastuzumab, Ribociclib [#] , Ribociclib [#] and Fulvestrant, Trastuzumab*, Trastuzumab emtansine	✓	
		Lapatinib, Neratinib		✓
	Colorectal cancer	Cetuximab, Panitumumab	✓	
		Bevacizumab		✓
	Gastric carcinoma	Trastuzumab*		✓
	Gastric, gastroesophageal junction or esophageal adenocarcinoma [^]	Nivolumab ^{^*} ,		✓
	Gastrointestinal tumour	Sunitinib*	✓	
	Head and neck cancer	Nivolumab*		✓
		Pembrolizumab*		✓
	Recurrent high grade glioma	Temozolomide	✓	
	Liver cancer	Lenvatinib ^{~*#}	✓	
		Atezolizumab* and Bevacizumab		✓

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Lung cancer	Afatinib, Alectinib [#] , Atezolizumab ^{*~} , Brigatinib ^{#~} , Ceritinib [#] , Crizotinib [#] , Durvalumab [~] , Gefitinib, Nivolumab ^{*~} , Osimertinib ^{**} , Pembrolizumab ^{*~}	✓	
		Atezolizumab [*] Lorlatinib, Nivolumab [*] and Ipilimumab [^] , Osimertinib ^{**} Pembrolizumab [*]		✓
	Malignant lymphoma	Rituximab	✓	
	Ovarian cancer	Pegylated Liposomal Doxorubicin		✓
	Epithelial ovarian / fallopian tube / primary peritoneal cancer	Bevacizumab, Niraparib [#] , Olaparib [#]		✓
	Prostate cancer	Abiraterone ^{**}	✓	✓
		Apalutamide ^{^#} Enzalutamide [#]	✓	
	Renal cell carcinoma	Axitinib [#] , Pazopanib	✓	
		Nivolumab [*] and Ipilimumab, Sunitinib [*]		✓
	Skin cancer	Dabrafenib ^{**} and Trametinib ^{**} , Nivolumab [*]	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
		Dabrafenib ^{**} and Trametinib ^{**} , Vemurafenib		✓
	Thyroid cancer [^]	Lenvatinib ^{^**}		✓
Ophthalmology	Macular oedema secondary to Central Retinal Vein Occlusion	Aflibercept, Ranibizumab	✓	
	Neovascular (wet) age-related macular degeneration	Aflibercept, Ranibizumab	✓	
	Non-infectious intermediate, posterior and panuveitis	Adalimumab	✓	
	Paediatric chronic non-infectious anterior uveitis	Adalimumab	✓	
	Visual impairment caused by diabetic macular edema	Aflibercept, Ranibizumab	✓	
Endocrinology	Dwarfism	Growth Hormone	✓	
Dermatology	Atopic dermatitis	Dupilumab, Upadacitinib [^]	✓	
	Hidradenitis suppurativa [^]	Adalimumab [^]	✓	
	Severe psoriasis	Adalimumab, Etanercept, Guselkumab, Infliximab, Ixekizumab, Risankizumab, Secukinumab, Ustekinumab	✓	
Clinical Immunology	Chronic spontaneous urticaria	Omalizumab	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
Paediatrics	Atopic Dermatitis	Dupilumab, Upadacitinib^	✓	
	CD20 positive diffuse large B-cell lymphoma, Burkitt lymphoma / Burkitt leukaemia or Burkitt-like lymphoma	Rituximab	✓	
	Classical Hodgkin Lymphoma (cHL)	Pembrolizumab*		✓
	Chronic granulomatous disease	Interferon	✓	
	Cryopyrin-associated periodic syndromes	Canakinumab	✓	
	Familial Mediterranean fever	Canakinumab	✓	
	Hyperimmunoglobulin D syndrome / mevalonate kinase deficiency	Canakinumab	✓	
	Tumour necrosis factor receptor associated periodic syndrome	Canakinumab	✓	
	Severe, active granulomatosis with polyangiitis (GPA) / microscopic polyangiitis (MPA)	Rituximab	✓	
	Juvenile Idiopathic Arthritis	Abatacept, Adalimumab, Etanercept, Tocilizumab	✓	
	Hidradenitis suppurativa^	Adalimumab^	✓	
	Severe psoriasis	Adalimumab	✓	

Specialties	Clinical Indications	Drugs	SF	CCF Medical Assistance Programme (1st Phase Programme)
	Systemic lupus erythematosus (SLE)	Belimumab	✓	
	Systemic juvenile idiopathic arthritis	Canakinumab, Tocilizumab	✓	

Remarks:

- ^ With effect from 16 December 2023.
- * The designated clinical indications of the same drug supported by different funds are different. Please consult your case doctor for details.
- ~ **Abemaciclib** for treating breast cancer; **Atezolizumab**, **Brigatinib**, **Durvalumab**, **Nivolumab** and **Pembrolizumab** for treating lung cancer; **Lenvatinib** for treating liver cancer; **Inotuzumab**, **Ozogamicin** for treating acute lymphoblastic leukaemia; and **Nivolumab** for treating skin cancer, are repositioned from CCF Medical Assistance Programme (First Phase Programme) to SF with effect from 16 December 2023. New applications and renewal applications approved on or after the effective date will be subsidised by SF. For applications already approved before the effective date, CCF subsidy will be provided until end of treatment of the applications.
- # The concerned drugs are under Capping Programmes where free drugs are subsequently provided through designated community pharmacies. For details, please refer to the [\[Information Sheet\]](#).

Patients who have financial difficulties may apply for assistance from the Fund. Eligible applicants may be given full or partial assistance of the treatment cost, depending on their financial situation

For details of drugs covered by the CCF Medical Assistance Programmes, namely the First Phase Programme and the “Subsidy for Eligible Patients to Purchase Ultra-expensive Drugs (Including Those for Treating Uncommon Disorders)”, please refer to the [CCF Medical Assistance Programmes](#) web page in the Hospital Authority Website.